DE2200940C2 - 9-substituierte Erythromycin-A und -B-oxime - Google Patents
9-substituierte Erythromycin-A und -B-oximeInfo
- Publication number
- DE2200940C2 DE2200940C2 DE2200940A DE2200940A DE2200940C2 DE 2200940 C2 DE2200940 C2 DE 2200940C2 DE 2200940 A DE2200940 A DE 2200940A DE 2200940 A DE2200940 A DE 2200940A DE 2200940 C2 DE2200940 C2 DE 2200940C2
- Authority
- DE
- Germany
- Prior art keywords
- oxime
- erythromycin
- oximes
- reaction
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims description 12
- 229960003276 erythromycin Drugs 0.000 title claims description 9
- 229930006677 Erythromycin A Natural products 0.000 title claims description 6
- IDRYSCOQVVUBIJ-UHFFFAOYSA-N Erythromycin-B Natural products CC1C(OC2C(C(CC(C)O2)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(C)C(CC)OC(=O)C(C)C1OC1CC(C)(OC)C(O)C(C)O1 IDRYSCOQVVUBIJ-UHFFFAOYSA-N 0.000 title claims description 5
- -1 B oximes Chemical class 0.000 title description 2
- IDRYSCOQVVUBIJ-PPGFLMPOSA-N erythromycin B Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 IDRYSCOQVVUBIJ-PPGFLMPOSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 239000000047 product Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- KYTWXIARANQMCA-PGYIPVOXSA-N (3r,4s,5s,6r,7r,9r,10z,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradec Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N\O)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYTWXIARANQMCA-PGYIPVOXSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- JFVYXJKGJMUGRG-KJPZRSJGSA-N Erythromycin a enol ether Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C2=C(C)C[C@](O2)(C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 JFVYXJKGJMUGRG-KJPZRSJGSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- OJHAHQJRQIOCFK-UHFFFAOYSA-N azane;chloroform;methanol Chemical compound N.OC.ClC(Cl)Cl OJHAHQJRQIOCFK-UHFFFAOYSA-N 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052806 inorganic carbonate Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10566471A | 1971-01-11 | 1971-01-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2200940A1 DE2200940A1 (de) | 1972-07-20 |
| DE2200940C2 true DE2200940C2 (de) | 1981-10-29 |
Family
ID=22307104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2200940A Expired DE2200940C2 (de) | 1971-01-11 | 1972-01-10 | 9-substituierte Erythromycin-A und -B-oxime |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3681326A (enExample) |
| JP (1) | JPS5629677B1 (enExample) |
| AU (1) | AU459269B2 (enExample) |
| CA (1) | CA955593A (enExample) |
| DE (1) | DE2200940C2 (enExample) |
| FR (1) | FR2121758B1 (enExample) |
| GB (1) | GB1336263A (enExample) |
| SE (1) | SE375535B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3855203A (en) * | 1973-05-03 | 1974-12-17 | Abbott Lab | 4{41 -o-sulfonyl erythromycin-9-o-oxime derivatives |
| US3979511A (en) * | 1974-05-23 | 1976-09-07 | Abbott Laboratories | Inhibitors of reverse transcriptase enzymes |
| US3963696A (en) * | 1975-02-21 | 1976-06-15 | Abbott Laboratories | 6,6A-AND 6,7-Anhydroerythromycin B and derivatives thereof |
| YU43006B (en) * | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
| US4526889A (en) * | 1982-11-15 | 1985-07-02 | Pfizer Inc. | Epimeric azahomoerythromycin A derivative, intermediates and method of use |
| ES552858A1 (es) | 1985-03-12 | 1987-11-01 | Beecham Group Plc | Un procedimiento para la preparacion de derivados de eritromicina. |
| US5932710A (en) | 1997-12-01 | 1999-08-03 | Abbott Laboratories | Process for preparing 6-O-alkyl-9-oxime erythromycin B |
| US20020187944A1 (en) * | 2001-03-21 | 2002-12-12 | Hung Paul Porwen | Inhibition of human immunodeficiency virus reverse transcriptase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU31319B (en) * | 1967-08-03 | 1973-04-30 | Pliva Pharm & Chem Works | Postupak za dobijanje acil derivata eritromicin oksima |
| GB1100504A (en) * | 1967-08-16 | 1968-01-24 | Pliva Pharm & Chem Works | Erythromycin oxime and 9-amino-3-o-cladinosyl-5-o-desosaminyl-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethylpentadecane-13-olide |
| ZA695765B (en) * | 1968-08-29 | 1971-03-31 | Lilly Co Eli | Erythromycylamine and process for preparing same |
-
1971
- 1971-01-11 US US105664A patent/US3681326A/en not_active Expired - Lifetime
- 1971-12-15 CA CA130,208A patent/CA955593A/en not_active Expired
- 1971-12-16 AU AU36998/71A patent/AU459269B2/en not_active Expired
- 1971-12-29 GB GB6056471A patent/GB1336263A/en not_active Expired
-
1972
- 1972-01-06 JP JP423272A patent/JPS5629677B1/ja active Pending
- 1972-01-10 DE DE2200940A patent/DE2200940C2/de not_active Expired
- 1972-01-10 SE SE7200235A patent/SE375535B/xx unknown
- 1972-01-11 FR FR7200832A patent/FR2121758B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CA955593A (en) | 1974-10-01 |
| JPS5629677B1 (enExample) | 1981-07-09 |
| AU3699871A (en) | 1973-06-21 |
| SE375535B (enExample) | 1975-04-21 |
| US3681326A (en) | 1972-08-01 |
| FR2121758A1 (enExample) | 1972-08-25 |
| AU459269B2 (en) | 1975-03-05 |
| FR2121758B1 (enExample) | 1975-10-10 |
| GB1336263A (en) | 1973-11-07 |
| DE2200940A1 (de) | 1972-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1795808C2 (de) | Verfahren zur Herstellung von 2,2,6,6-Tetramethyl-4-oxopiperidin | |
| DE2200940C2 (de) | 9-substituierte Erythromycin-A und -B-oxime | |
| DE2750812A1 (de) | Anthracyclinderivate und verfahren zu deren herstellung | |
| WO2008138605A2 (de) | Verfahren zur herstellung von n-methylnaltrexonbromid | |
| EP0608693B1 (de) | Verfahren zur Herstellung von Folsäure | |
| DE2022656C3 (de) | 2-(Nicotinoylaminoäthansulfonylamino) pyridin | |
| DE3035395A1 (de) | Verfahren zur herstellung von pyrazol | |
| AT391866B (de) | Verfahren zur herstellung neuer s-triazolo (1,5-a) pyrimidine | |
| DE2000030C3 (de) | 3-Alkoxy-und 3-Phenoxy-2-(diphenylhydroxy)methyl-propylamine und diese enthaltende Arzneimittel | |
| DE3223877C2 (enExample) | ||
| DE60014330T2 (de) | Verfahren zur herstellung von 1,4,7,10-tetraazacyclododecan | |
| DE2519157A1 (de) | Verfahren zur herstellung von glycosiden mit antitumorwirksamkeit | |
| DE1670152C2 (de) | N-substituierte Granatanol-tropasäureester und ein Verfahren zu ihrer Herstellung | |
| DE3102984A1 (de) | Verfahren zur herstellung von cysteamin-s-substituierten verbindungen und deren derivaten | |
| EP2167506B1 (de) | Verfahren zur herstellung von n-methylnaltrexonbromid | |
| AT365598B (de) | Verfahren zur herstellung eines neuen formamidkomplexes von 7-beta-(d-2-phenylacetamido) -3-methylceph-3-emcarbonsaeure | |
| DE1695580C (de) | Quaternare Verbindungen des Benzil saure beta piperidino athylesters und ein Verfahren zu ihrer Herstellung | |
| DE2024983C3 (de) | Hydrogensulfate quaternärer Tetraalkylammoniumverbindungen, Verfahren zu deren Herstellung und deren Verwendung | |
| DE1620223A1 (de) | Verfahren zur Herstellung von Oxaphenanthridinen | |
| DE3714438A1 (de) | Optisch aktive dihydropyridinlactone, verfahren zu ihrer herstellung und ihre verwendung | |
| CH412887A (de) | Verfahren zur Herstellung von Additionssalzen des 1-Methyl-3-(di-2-thienylmethylen)-piperidins | |
| DE1155437B (de) | Verfahren zur Herstellung von Phospho-enolbrenztraubensaeuredibenzylester | |
| DE2459614A1 (de) | Mono-und diester der 2,5-dihydroxybenzolsulfonsaeure, verfahren zu ihrer herstellung und arzneimittel | |
| DE2363536B2 (de) | Verfahren zur Herstellung von 2,2'-Anhydro-l-ß-Darabinofuranosyl- 5-fluorcytosin | |
| DE1518050B1 (de) | Verfahren zur Herstellung von Methioninmethylsulfoniumsalzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| D2 | Grant after examination | ||
| 8339 | Ceased/non-payment of the annual fee |